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ABSTRACT
The promising treatment combination of ionizing radiation (IR) with a hypoxia-
activated prodrug (HAP) is based on biological cooperation. Here we investigated 
the hypoxia-activated prodrug evofosfamide in combination with different treatment 
regimens of IR against lung A549- and head&neck UT-SCC-14-derived tumor 
xenografts. DNA damage-related endpoints and clonogenic cell survival of A549 and 
UT-SCC-14 carcinoma cells were probed under normoxia and hypoxia.
Evofosfamide (TH-302) induced DNA-damage and a dose-dependent 
antiproliferative response in A549 cells on cellular pretreatment under hypoxia, and 
supra-additively reduced clonogenic survival in combination with IR. Concomitant 
treatment of A549-derived tumor xenografts with evofosfamide and fractionated 
irradiation induced the strongest treatment response in comparison to the 
corresponding neoadjuvant and adjuvant regimens. Adjuvant evofosfamide was more 
potent than concomitant and neoadjuvant evofosfamide when combined with a single 
high dose of IR. Hypoxic UT-SCC-14 cells and tumor xenografts thereof were resistant 
to evofosfamide alone and in combination with IR, most probably due to reduced 
P450 oxidoreductase expression, which might act as major predictive determinant 
of sensitivity to HAPs.
In conclusion, evofosfamide with IR is a potent combined treatment modality 
against hypoxic tumors. However, the efficacy and the therapeutic outcome of this 
combined treatment modality is, as indicated here in preclinical tumor models, 
dependent on scheduling parameters and tumor type, which is most probably related 
to the status of respective HAP-activating oxidoreductases. Further biomarker 
development is necessary for the launch of successful clinical trials.
INTRODUCTION
Radiotherapy, along with surgery and chemotherapy 
is one of the major treatment options for solid tumors. 
However, solid tumors are often radiation resistant due to 
tumor hypoxia, which thereby represents a major clinical 
challenge. Several strategies have been developped 
during the last decades to overcome the hurdle of tumor 
hypoxia for successful radiotherapy [1–4]. One of these 
concepts is based on biological cooperation, which refers 
to strategies that target distinct cell populations, or employ 
different mechanisms for cell killing. The combination 
of ionizing radiation (IR) with a Hypoxia-Activated 
Prodrug (HAP), targeting hypoxic tumor cells and thereby 
complementing the effect of IR in well-oxygenated cells, 
nicely represents the concept of biological cooperation [5]. 
Originally, nitrobenzenes, followed by the nitroimidazoles 
(misonidazole, etanidazole, pimonidazole) [6], were 
proposed to act as oxygen mimetic agents and to generate 
together with short-lived IR-induced free DNA radicals 
cytotoxic DNA strand breaks [7, 8]. Unfortunately, and 
despite the clarity of the concept, severe toxicities of these 
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early generation compounds have contributed that these 
hypoxic radiosensitizers did not find their recognition in 
the clinical routine. Nevertheless these findings paved the 
way for the generation of hypoxia-selective bioreductive 
prodrugs, which are activated by enzymatic reduction in 
hypoxic tissues [9].
This risk of severe side-effects is reduced with 
HAPs that are less toxic and especially with compounds 
that are only activated under severe hypoxia. At the same 
time such prodrugs should release a diffusible, active 
cytotoxic agent, not only to kill the most hypoxic tumor 
cells, but also to induce a bystander effect thereby killing 
tumor cells of intermediate levels of tumor hypoxia. The 
2-nitroimidazole-conjugated bromo-isophosphoramide 
mustard (Br-IPM) evofosfamide (TH-302) represents a 
prototype of such a novel generation HAP. Evofosfamide 
is currently the most advanced compound in clinical trials 
of the new generation of bioreductive cytotoxins [10–12].
The development of linear accelerator technology 
for the precise delivery of radiotherapy has nowadays 
reached a level of dose conformity to the tumor that allows 
the application of high dose fractions (even > 10 Gy) to 
small tumors with very steep dose gradients. Fractionated 
application of daily doses of IR exploits reoxygenation of 
hypoxic tumor regions in between fractions and thereby 
overcomes the hypoxic challenge as part of an iterative 
process. On the other hand single high doses of IR or a 
hypofractionated treatment regimen requires other means 
to improve its efficacy and to control a hypoxic tumor e.g. 
by the combined treatment modality with a HAP [13, 14].
Here we investigated the potency of evofosfamide in 
combination with fractionated and single high-dose of IR 
and tested these regimens in three settings (neoadjuvant, 
concomitant and adjuvant) routinely applied in clinical 
practice. Furthermore, the influence of treatment 
conditions linked to the individual geno- and phenotype 
of the tumor, including the status of the HAP-activating 
oxidoreductases, DNA-damage repair machineries and the 
hypoxic burden, was analyzed.
RESULTS
Evofosfamide in combination with IR in vivo
The combined treatment modality of IR with an 
HAP is based on biological cooperation. However, the 
most effective scheduling of the two modalities is not 
predictable. We therefore probed three different treatment 
schedules (neoadjuvant, concomitant and adjuvant) of a 
minimally fractionated irradiation regimen (3x2 Gy on 3 
consecutive days) and evofosfamide (50 mg/kg, Q3Dx5) 
in a lung adenocarcinoma (A549) and a head&neck 
squamous cell carcinoma (UT-SCC-14) tumor xenograft 
model. The dosage and schedule of evofosfamide was 
defined based on previous preclinical reports when 
used as part of a combined treatment modality [15] and 
closely mimic the settings used in clinical practice. 2 
Gy per fraction of IR corresponds to the dose/fraction 
used as part of a clinical fractionated radiotherapy 
treatment regimen. Both tumor models were previously 
characterized to develop tumors with an intermediate 
hypoxic tumor fraction [16, 17]. Tumor hypoxia was 
also confirmed by pimonidazole staining (Supplementary 
Figure 1). Treatment was initiated when tumors reached a 
volume of 300 mm3 (+/- 10%). Treatment of A549-derived 
tumor xenografts with evofosfamide in combination with 
fractionated irradiation resulted in a strongly enhanced 
treatment response when compared to treatment with 
evofosfamide and irradiation alone (Figure 1A). The 
concomitant schedule induced the strongest tumor 
growth delay (P<0.05 for evofosfamide plus IR versus 
each monotherapy), however, no statistically significant 
differences in between the three combined treatment 
regimens could be determined. Interestingly, evofosfamide 
alone did not reduce tumor growth of HNSCC UT-SCC-14 
xenografts and did not enhance the growth inhibitory 
effect of fractionated irradiation as part of a combined 
treatment modality (Figure 1B). These results suggest that 
the response to evofosfamide and IR is highly dependent 
on the tumor type.
Due to the differential treatment response in the two 
tumor models in vivo, the effect of evofosfamide was also 
determined in vitro with defined hypoxic conditions (0.2% 
O2). Interestingly, A549 cells were also more sensitive than 
UT-SCC-14 to increasing concentrations of evofosfamide 
(Supplementary Figure 2). The cytochrome P450 
oxidoreductase (POR) has previously been identified as 
major determinant for the sensitivity of hypoxia-activated 
prodrugs [18, 19]. Therefore, the expression level of POR 
was determined on the cellular and tumor level by western 
blotting and immunohistochemistry, respectively. The 
POR expression level was strongly reduced in UT-SCC-14 
cells and UT-SCC-14-derived tumors in comparison 
to A549 cells and tumors derived thereof (Figure 2A, 
2B). This is most probably the cause for evofosfamide-
resistance against the head&neck tumor model used in 
this study. Furthermore, transient downregulation of 
POR in A549 cells with POR-directed siRNA resulted in 
reduced sensitivity to evofosfamide in these cells relative 
to control siLUC-transfected A549 cells (Supplementary 
Figure 3), reinforcing the role of POR for evofosfamide 
sensitivity. Despite several attempts, we could not perform 
the opposite experimental approach to overexpress POR 
in UTSCC-14 cells. These cells did always undergo cell 
death upon genetic manipulation alone.
To further analyze the differential treatment 
response in between A549 and UT-SCC-14-derived 
tumors, comprehensive analysis of hypoxia-related 
secreted factors was performed by Bio-plex analysis. 
Unfortunately, the levels of serum secreted factors in 
mice carrying tumor xenografts were below detection 
limits. Therefore, in vitro analysis of conditioned media 
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derived from A549 and UT-SCC-14 cells was performed. 
The basal secretory levels of most factors analyzed were 
different in between the two cell lines (e.g. VEGF, IL-
6, Osteopontin, sEGFR, TNFα) and did not change in 
response to evofosfamide treatment (Supplementary 
Figure 4). Interestingly, placental growth factor (PlGF) 
was strongly increased in A549 but not in UT-SCC-14 
cells in response to evofosfamide, suggesting that an 
increase of PlGF might be used as an early response 
biomarker (Figure 2C).
Next, the potency of evofosfamide was investigated 
in the evofosfamide-sensitive A549-derived tumor model 
as part of a combined treatment modality (neoadjuvant, 
concomitant, adjuvant) with a single high dose of IR (10 
Gy). The adjuvant combined treatment modality was 
most effective and induced a strong tumor growth delay 
in comparison to evofosfamide and IR alone (P<0.05 
for evofosfamide plus IR versus each monotherapy). 
Concomitant treatment with IR and evofosfamide only 
induced a partial additive tumor growth delay. On the other 
hand tumors almost doubled in size during the time period 
of neoadjuvant treatment with evofosfamide. Thereby 
tumors were irradiated at an increased tumor volume with 
a single high dose of IR, resulting in a reduced overall 
treatment response to the neoadjuvant combined treatment 
regimen (Figure 3A, 3B).
Enhanced radiosensitivity upon evofosfamide 
treatment in vitro
In vitro experiments with A549 cells demonstrated 
a dose- and hypoxia incubation time-dependent 
antiproliferative effect of evofosfamide (Figure 4A). To 
determine cancer cell clonogenicity, A549 cells were 
incubated with evofosfamide (0.5 μM) for 4 hours under 
hypoxia (0.2% O2) and normoxia, respectively, followed 
by irradiation under reoxygenated conditions. Combined 
treatment of A549 cells with evofosfamide and increasing 
doses of IR resulted in a strong, supra-additive reduction 
of clonogenicity when cells were preincubated with 
Figure 1: Treatment response to evofosfamide and fractionated irradiation in vivo. Tumor growth delay of A549-derived 
(A) and UT-SCC-14-derived (B) tumor xenografts in response to different treatment schedules of the combined treatment modality with 
evofosfamide (50 mg/kg, Q3Dx5) and fractionated irradiation (3x2 Gy). Control mice were treated i.p. with saline. Neoadjuvant (left 
panel), concomitant (middle panel), and adjuvant (right panel) regimens are shown. Neoadjuvant (left panel), with evofosfamide given on 
days 1-12 followed by fractionated irradiation; concomitant (middle panel), with evofosfamide given on days 1-12 and IR on days 5-7; 
adjuvant (right panel), IR given on days 0-2 (fractionated) followed by treatment with evofosfamide. 7-8 mice per treatment groups were 
used. Error bars represent SEM. (C) Kaplan-Meier curves for A549-derived tumors reaching 600mm3 tumor volume.
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Figure 2: Differential POR- and PLGF-levels in A549 and UT-SCC-14 tumors. (A) Protein levels of cytochrome P450 
oxidoreductase (POR) in A549 and UT-SCC-14 cells incubated under normoxia (21% O2) and hypoxia (0.2% O2, 24 hours) as determined 
by western blotting. (B) Staining of A549 (left) and UT-SCC-14 (right)-derived tumor xenografts sections with anti–POR antibodies. 
(C) Levels of secreted PLGF in A549 and UT-SCC-14 conditioned medium in normoxia (21% O2) and hypoxia (0.2% O2, 24 hours) as 
determined using Bio-plex assay. Data are shown as fold induction over non-treated normoxic samples in three independent experiments, 
error bars represent SEM.
Figure 3: Treatment response to evofosfamide and single high-dose irradiation in vivo. Tumor growth delay of A549-derived 
xenografts in immunocompromised mice in response to combined treatment with evofosfamide (50 mg/kg, Q3Dx5) and single high-dose 
IR (1x10 Gy). Control mice were treated i.p. with saline. (A) Neoadjuvant (left panel), concomitant (middle panel), and adjuvant (right 
panel) regimens are shown. Neoadjuvant (left panel), with evofosfamide given on days 1-12 followed by irradiation; concomitant (middle 
panel), with evofosfamide given on days 1-12 and IR on day 6; adjuvant (right panel), IR given on day 0 followed by treatment with 
evofosfamide. 7-14 mice per treatment groups were used. Error bars represent SEM. (B) Kaplan-Meier curves for tumors reaching 600mm3 
tumor volume.
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evofosfamide under hypoxic conditions in comparison to 
preincubation under normoxic conditions (DEF0.1=1.44+/-
0.07 vs DEF0.1 of 1.16 +/- 0.07 respectively, and 
DEF0.37=1.72+/-0.12 vs DEF0.37=1.23+/-0.24, respectively) 
(Figure 4B).
The adjuvant schedule of evofosfamide in 
combination with IR resulted in a strong tumor growth 
delay in vivo. Therefore a reversed schedule with 
irradiation of cells (2 Gy) followed by incubation with 
evofosfamide (0.5 μM for 4 hours, 0.2% O2) was also 
probed in vitro. Combined treatment also resulted 
in a statistically significant increase of cell killing in 
comparison to cellular treatment with evofosfamide and 
IR alone (Figure 4C).
Induction of DNA damage and senescence in 
response to evofosfamide
Activation of the prodrug evofosfamide results in 
the potent DNA-alkylating agent bromo isophosphoramide 
mustard and induces a strong DNA damage response. 
Residual DNA damage was determined by γH2AX foci 
Figure 4: Treatment response to evofosfamide and irradiation in vitro. (A) Proliferation of A549 lung adenocarcinoma cells 
in response to increasing doses of evofosfamide. Cells were pre-incubated in hypoxia (0.2% O2) for 23 hours, followed by treatment with 
increasing concentrations of evofosfamide under hypoxic conditions for 1 hour (left panel). Proliferation of A549 cells pre-incubated for 
23, 18 and 2h in hypoxia (0.2% O2), followed by treatment with evofosfamide (0.5 μM) under hypoxia for 1, 6 and 22 hours, respectively 
(right panel). The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) To determine time-dependent effects of 
evofosfamide, cells were incubated for 23, 18 and 2h in hypoxia (0.2% O2), followed by treatment with evofosfamide (0.5 μM) for 1, 6 
and 22 hours, respectively. The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) Clonogenic cell survival 
assay of A549 cells treated with 0.5 μM evofosfamide under normoxic (21% O2) and hypoxic (0.2% O2) conditions for 4 hours. Following 
reoxygenation, cells were irradiated with increasing doses of IR. (C) Clonogenic survival assay of lung carcinoma A549 cells irradiated 
with 2 Gy and treated thereafter with evofosfamide (0.5 μM) under normoxic (21% O2) and hypoxic (0.2% O2) conditions for 4 hours 
(adjuvant setting); Error bars represent SEM.
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detection in A549 cells on treatment with evofosfamide 
and IR alone and in combination. As expected, a high level 
of residual DNA-damage was present at the 24 hour time 
point on initial cellular incubation with evofosfamide for 
4 hours under hypoxic but not under normoxic condition. 
Interestingly, combined treatment with irradiation (2 Gy) 
only resulted in a minimal but statistically not significant 
additional increase of residual DNA damage (Figure 5A). 
Lack of additional residual γH2AX foci in cells treated 
with both modalities does not correspond with the supra-
additive cell killing by the combined treatment modality 
in vitro (see above Figure 4B, 4C). Similar results were 
obtained when DNA damage was probed on the level of 
residual 53BP1-foci (Supplementary Figure 5).
Senescence is a well-known mode of cell death 
induced upon treatment with alkylating agents [20]. A 
high percentage of β-galactosidase positive A549 cells was 
induced on treatment with evofosfamide under hypoxic 
conditions, which was further increased on combined 
treatment with IR (Figure 5B). These results demonstrate 
that evofosfamide alone induces a strong DNA damage 
response and senescence in lung carcinoma cells. The 
small increase in the number of senescent cells in response 
to evofosfamide in combination with IR corresponds 
in part with decreased clonogenicity of A549 cells in 
response to this combined treatment modality.
Increased cell killing by evofosfamide in BRCA2-
deficient ovarian carcinoma cells
Evofosfamide-induced DNA damage requires 
homologous recombination for efficient DNA repair as 
previously shown in non-tumorigenic chinese hamster 
ovary cells [19]. To further investigate evofosfamide 
in combination with IR in tumorigenic cell lines and 
with defined HR-deficiency, proliferative activity and 
clonogenicity was determined in the BRCA2-wildtype 
PEO4 and the otherwise genetically identical BRCA2-
deficient ovarian carcinoma cell line PEO1 [21]. As 
expected, BRCA2-deficient PEO1 cells were more 
sensitive to increasing concentrations of evofosfamide 
in comparison to BRCA2-wildtype PEO4 cells under 
hypoxic conditions (Figure 6A). Moreover, combined 
treatment with IR reduced clonogenic cell survival in 
Figure 5: DNA damage in response to evofosfamide and irradiation. (A) Residual γH2AX foci were analyzed in A549 cells 
treated for 4 hours with evofosfamide and irradiation with 2 Gy. Cells were analyzed 20 hours after irradiation at a magnification of 40x. (B) 
Induction of senescence (β-galactosidase staining) in response to the combined treatment in A549 cells. Cells were analyzed 72 hours after 
treatment at a magnification of 10x. At least 50 cells/condition were analyzed. Representative pictures are shown. Error bars represent SEM.
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PEO1 cells to a higher extent than in the BRCA2-wildtype 
counterpart cells (Figure 6B). The ratio of survival 
fractions in response to evofosfamide and evofosfamide 
in combination with IR was 25.5 and 17.9 for PEO1 and 
PEO4 cells, respectively. The ratio of survival fractions 
in response to IR and the combined treatment modality 
was 7.1 and 2.7 for PEO1 and PEO4, respectively. These 
results strongly indicate a superior appliance for this 
combined treatment modality in tumors with homologous 
recombination-deficiency.
DISCUSSION
Evofosfamide is one of the most promising 
hypoxia-targeting agents currently tested in several 
clinical trials. Here we have investigated the combined 
treatment modality of evofosfamide with IR in a lung 
and a head&neck carcinoma model with a specific 
focus on multiple treatment regimens and schedulings. 
IR is known to target primarily well-oxygenated 
cells, while hypoxic cells are radiation-resistant. 
Therefore, the combined treatment modality of IR with 
evofosfamide is based on the promising rationale named 
biological cooperativity [5]. Both tumor models stained 
positive and to similar extent for the hypoxia-marker 
pimonidazole, however head&neck tumor xenografts 
were completely resistant to evofosfamide alone and 
when combined with IR, independent of the treatment 
scheduling. Subsequent expression studies revealed 
strongly reduced cytochrome P450 oxidoreductase 
(POR) levels in this tumor model. On the other hand 
A549 cells and A549 -derived tumor xenografts stained 
POR-positive and were highly evofosfamide-sensitive 
in vitro and in vivo.
Recently the dual combined treatment modality of 
IR with evofosfamide was shown to enhance the effect of 
radiotherapy in a rhabdomyosarcoma R1 and in a H460-
derived non-small-cell lung cancer tumor model and as 
part of a trimodality therapy in sarcoma models with the 
anti-VEGF receptor-directed antibody DC101 [15, 22]. In 
both studies only single high doses of IR were applied and 
scheduling of evofosfamide with IR was not investigated.
We here tested three different treatment regimens 
(neoadjuvant, concomitant, adjuvant) in combination 
with fractionated and single high-dose IR in the lung 
adenocarcinoma tumor model. A more potent neoadjuvant 
and concomitant versus adjuvant scheduling of the 
combined treatment modality of evofosfamide with 
fractionated IR was identified, which might coincide with 
evofosfamide initially targeting the major tumor hypoxic 
burden followed by fractionated irradiation including 
partial reoxygenation of the remaining hypoxic areas.
On the other hand the more potent adjuvant 
scheduling of evofosfamide in combination with a single 
high dose of IR could be due to an (transient) increase 
of tumor hypoxia in response to single high doses of 
IR [23, 24]. Interestingly own experiments performed 
independently of this study also demonstrated an increase 
of tumor hypoxia over time in response to a single high 
dose of IR in this tumor model (Supplementary Figure 
6). Similar to former studies with evofosfamide we only 
considered tumor growth delay as an endpoint and the 
hypoxic situation might vary in between different tumors. 
As such these schedulings will have to be carefully 
translated to the clinical situation.
Several studies on the activation of HAPs previously 
demonstrated that cytochrome P450 oxidoreductase is 
indispensable for several HAPs [18, 19, 25]. However, its 
Figure 6: Treatment response of BRCA2-deficient (PEO1) and BRCA2-wild-type (PEO4) ovarian carcinoma cells to 
evofosfamide and irradiation. (A) Cells were pre-incubated in hypoxia (0.2% O2) for 20 hours, followed by treatment with increasing 
concentrations of evofosfamide for 4 hours. The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) Clonogenic 
cell survival assay of BRCA2 deficient (PEO1) and wild-type (PEO4) cells in response to evofosfamide (0.5 μM) and irradiation with 4 
Gy. Cells were pre-incubated in hypoxia (0.2% O2) for 20 hours, followed by evofosfamide treatment under hypoxic conditions (4 hours), 
reoxygenation and irradiation with 4 Gy. Error bars represent SEM.
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relevance for the nitroimidazole mustard evofosfamide is 
less clear. Su et al. knocked-out POR in multiple tumor 
cell lines that resulted in resistance to several one-electron 
reductase substrates but not to evofosfamide, suggesting 
the existence of structure-dependent oxidoreductase 
redundancies [26]. On the other hand, Hunter et al. recently 
demonstrated reduced cytotoxicty of evofosfamide in 
head&neck carcinoma cells with shRNA-downregulated 
POR-expression [18]. More important, a heterogeneous 
POR expression status was retrospectively determined in 
head&neck squamous cell carcinoma patient samples, and 
suggests that POR might be a major predictive determinant 
for HAPs including evofosfamide [18]. Our own studies, 
which were performed on the cellular level and to our best 
knowledge for the first time also in vivo, strongly suggest 
that POR co-determines the potency of evofosfamide. As 
such we demonstrate minimal efficacy of evofosfamide in 
vivo in hypoxic tumor xenografts generated from a patient-
derived head&neck carcinoma [27].
Only recently two phase III trials of evofosfamide 
in advanced soft-tissue sarcoma and in advanced 
pancreatic cancer in combination with doxorubicin and 
gemcitabine, respectively, did not meet their primary 
endpoints of improved overall survival (CancerNetwork 
Oncology, December 2015). Our in vivo data suggest the 
treatment combination of evofosfamide with radiotherapy 
is still of strong interest but requires detailed efficacy- 
and mechanistic-oriented studies towards a successful, 
personalized treatment approach. Our data demonstrate 
that both tumor hypoxia and the POR-status are strong 
co-determinant for the efficacy of evofosfamide. Thus, 
specific image- and gene expression-guided biomarker 
analysis to determine tumor hypoxia but also HAP-
activation are required for optimized patient stratification. 
Serial analysis of serum factors specifically released in 
response to evofosfamide could represent a valid strategy 
to identify at an early stage evofosfamide-responsive 
tumors. We probed several angiogenesis- and hypoxia-
related serum factors in response to evofosfamide. 
Interestingly only secretion of the placental growth factor 
(PlGF) was increased on treatment by evofosfamide under 
hypoxia and only by the evofosfamide-responsive and not 
by the evofosfamide-resistant carcinoma cells. Our in vitro 
data also corroborate that evofosfamide in combination 
with IR is more potent in BRCA2-deficient tumor cells 
than in their BRCA2-wildtype counterpart cells. Previous 
studies were only performed in genetically-defined CHO-
cells and in combination with cisplatinum against tumor 
cells [18, 19].
Thus, it will be of highest interest to follow the 
results of the first clinical study by Larue and colleagues, 
testing evofosfamide with preoperative chemoradiotherapy 
in oesophageal adenocarcinoma patients [28]. This 
study includes repeated hypoxia PET imaging and blood 
sampling to determine hypoxia blood markers and could 
also incorporate testing of POR, PlGF and a putative 
homologous recombination-corrupted genetic background 
as part of their translational endpoints. Investigated dose 
levels of evofosfamide will range from 120 mg/m2 to 340 
mg/m2 in this clinical study. However, it will be difficult 
to compare these dose levels with the drug concentrations 
applied in our animal study due to the differential route of 
drug administration and the differential drug metabolism 
between humans and mice. For comparative reasons we used 
similar concentrations of evofosfamide doses in our study as 
in the previous preclinical study by Peters et al. [15].
Overall our data demonstrate that evofosfamide 
with IR is a potent combined treatment modality 
against hypoxic tumors. Our preclinical data suggest 
that its efficacy on the clinical level could eventually be 
dependent on scheduling parameters and tumor type. 
Furthermore, several conditions linked to the individual 
geno- and phenotype of the tumor including the status of 
the HAP-activating oxidoreductases, DNA-damage repair 
machineries and the hypoxic burden have to be fulfilled, 
rendering this combined treatment modality highly potent 
towards a personalized treatment approach.
MATERIALS AND METHODS
Cell lines and compounds
The human non-small cell lung cancer (NSCLC) 
cell line A549 was obtained from ATCC and cultured in 
RPMI 1640 cell culture media supplemented with 10% 
FBS, glutamine (2 mM) and penicillin-streptomycin 
(100 U/ml-100 μg/ml). The head&neck squamous cell 
carcinoma (HNSCC) UT-SCC-14 cell line was a kind 
gift from Reidar Grénman (Turku University Hospital, 
Finland) and was maintained in DMEM, high glucose, 
NEAA, 10% FCS, 2 mM L-glutamine, 1% Penicillin/
Streptomycin (100 U/ml-100 μg/ml) and 1 mM sodium 
pyruvate [27]. The ovarian cancer cells PEO4 and 
PEO1 were purchased from the Health Protection 
Agency Culture Collections (Salisbury, UK) and were 
kept in RPMI 1640 cell culture media supplemented 
with 10% FBS, glutamine (2 mM), sodium pyruvate (2 
mM) and penicillin-streptomycin (100 U/ml-100 μg/
ml). For normoxic conditions, cells were kept in a 5% 
CO2 incubator at 37°C, for hypoxic conditions, cells 
were kept in a 0.2% O2, 5% CO2, incubator (In vivo2 
300-Ruskinn; Hypoxia Incubator, Siemens) at 37°C. 
Evofosfamide was obtained from Merck KGaA.
Cell proliferation and clonogenic cell survival 
assay
The proliferative activities of tumor cells were 
assessed in 96-well plates with the colorimetric 
alamarBlue assay (Invitrogen). Cells were preincubated 
under hypoxia and treated for the indicated time intervals 
and concentrations of evofosfamide in either normoxic 
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(21% O2) or hypoxic (0.2% O2) conditions. Clonogenic 
cell survival was determined by the ability of single cells 
to form colonies in vitro as described before [29]. Cells 
were treated with 0.5 μM of evofosfamide for 4 hours in 
either normoxic (21% O2) or hypoxic (0.2% O2) conditions 
or as described in the figure legend. Thereafter cells were 
reoxygenated and irradiated with increased doses of IR 
and trypsinized. To probe the adjuvant scheduling, cells 
were first irradiated with 2 Gy, followed by addition of 
evofosfamide and incubation of cells in either normoxic 
or hypoxic conditions for 4 hours. Single cell suspensions 
were seeded into 10 cm-petri dishes. The number of plated 
cells per dish was adjusted to obtain approx. 50-100 
colonies under all experimental conditions. After colony 
formation (depending on cell lines, approx. 14 days), 
colonies were fixed (methanol/acetic acid; 3:1) and stained 
with crystal violet (2%). Colonies (containing > 50 cells) 
were then counted manually.
Tumor xenografts and application of treatment 
regimes
A549 lung carcinoma and UT-SCC-14 head&neck 
squamous cell carcinoma cells were subcutaneously 
injected on the back of four week old, female CD1 
athymic nude mice (Charles River). Tumor volumes were 
determined from caliper measurements of tumor length 
(L) and width (l) according to the formula (L x l2)/2. 
Treatment was initiated when tumors reached a volume 
of 300 mm3 +/- 10%. Tumors were sham-irradiated or 
irradiated using a customized shielding device with either 
a fractionated (3x2 Gy) or a single high dose regimen 
(1x10 Gy) using an Xstrahl 200 kV X-ray unit at 1 Gy/
min. Evofosfamide (50 mg/kg in saline) or saline was 
administered i.p. Q3Dx5. Three treatment regimens were 
investigated: neoadjuvant, with evofosfamide on days 1-12 
followed by either a fractionated or a high dose regimen; 
concomitant, with evofosfamide on days 1-12 and IR on 
days 5-7 (fractionated) or day 6 (high dose); adjuvant, IR 
on days 0-2 (fractionated) or day 0 (high dose) followed 
by treatment with evofosfamide. All in vivo experiments 
were performed according to the guidelines for the welfare 
and use of animals of the Veterinäramt Kanton Zürich, 
Switzerland.
Bio-plex multiplex assay
A549 lung carcinoma and UT-SCC-14 head&neck 
squamous cell carcinoma cells were seeded in 6-well 
plates at the density of 150-200’000 cells/well in 
DMEM medium (high glucose, NEAA, 10% FCS, 2 
mM L-glutamine, 1% Penicillin/Streptomycin and 1 
mM sodium pyruvate). Cells were irradiated with 5 Gy 
followed by addition of evofosfamide (0.5; 1 μM) and 
placed in either normoxic (21% O2) or hypoxic conditions 
(0.2% O2). After 24 hour incubation, conditioned medium 
was collected, filtered through an 0.45 μM filter and 
stored at -20° C until analysis. A customized Bio-plex 
Biomarker Cancer Panel assay was performed with 
undiluted conditioned medium samples according to the 
manufacturer protocol (Bio-Rad). Obtained concentrations 
of measured samples (pg/ml) were normalized to the 
cell number and are shown as fold induction relative to 
the determined concentrations derived from normoxic 
untreated control samples.
Western blotting and immunohistochemistry
For western blot analysis, A549 and UT-SCC-14 
cells were incubated in either normoxic (21% O2) or 
hypoxic conditions (0.2% O2) for 24 hours, followed by 
lysis in RIPA buffer (Sigma) and SDS-PAGE. Membranes 
were incubated with primary anti-Cytochrome P450 
Reductase (POR/CYPOR) antibodies (Santa Cruz 
Biotechnology (G-5): sc-25263; 1:100) and mouse 
monoclonal anti–β-actin antibody (Sigma Aldrich, 
#A5441, 1:1000), followed by secondary anti-mouse 
ECL IgG HRP-linked (GE Healthcare, NA931V, 1:2000). 
Immunohistological endpoints were analyzed on paraffin-
embedded blocks of A549 and UT-SCC-14-derived tumor 
xenografts using anti-POR (Invitrogen, PA5-27326; 1:100) 
and anti-pimonidazole (Hypoxyprobe, HP1-1000, 1:100) 
antibodies.
γH2AX and 53BP1 foci staining
A549 cells were preincubated in hypoxic conditions 
(0.2% O2) for 20 hours, followed by treatment with 
evofosfamide for 4 hours under hypoxic conditions, 
reoxygenation and irradiation with 2 Gy. 20 hours after 
irradiation, cells were washed twice with PBS, fixed with 
4% formaldehyde/PBS for 10 min, and washed with PBS 
(4 x 5 min). Cells were then permeabilized for 5 min with 
0.2% ice cold Triton-X-100/PBS, blocked for at least 
20 min with 1% BSA, followed by 1 hour incubation 
with the rabbit monoclonal anti-H2AX-pSer139 (1:100, 
Abcam, Cambridge, UK) or the rabbit polyclonal anti-
53BP1 (1:200, Cell Signaling, Boston MA, USA) primary 
antibodies, diluted in 1% BSA/PBS. After washing 
with 1% BSA/PBS (3 x 15 min), cells were incubated 
with the appropriate secondary antibody diluted 1:1000 
(Alexa-488), washed with 1% BSA/PBS (2 x 10 min) 
followed by PBS (1 x 10 min) and incubated with DAPI/
Methanol (1 μg/ml) for 3 min, before fixation with Dako 
Fluorescent Mounting Medium (Dako, North America). 
Images were taken using a Leica DM 5500 microscope at 
a magnification of 40x and quantified using FociCounter 
software. At least 50 cells/condition were analyzed.
Analysis of cellular senescence
A549 cells were preincubated in hypoxic conditions 
(0.2% O2) for 20 hours, followed by treatment with 
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evofosfamide for 4 hours under hypoxic conditions, 
reoxygenation and IR with 2 Gy. 72 hours after 
irradiation, cells were stained for β-galactosidase using the 
Senescence β-Galactosidase Staining Kit (Cell Signaling, 
#9860): cells were washed with PBS and fixed (with 2% 
formaldehyde, 0.2% glutaraldehyde in PBS) for 15 min 
at room temperature. Cells were washed twice with PBS 
and stained with 40 mM citric acid/sodium phosphate 
(pH 6.0), 0.15 M NaCl, 2 mM MgCl2, 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide, 1 mg/ml 
X-gal (5-bromo-4-chloro-3-indolyl-βD-galactopyranoside) 
for 24 hours at 37°C. β-galactosidase-positive cells were 
counted in at least 3 randomly chosen visual fields at a 
magnification of 10x in each treatment setup.
Short interfering RNA treatment
A549 cells were transfected with POR-directed 
siRNA (Santa Cruz Biotechnology) for 24h using 
Lipofectamine RNAiMAX (Invitrogen). Cells were 
preincubated under hypoxia (0.2% O2) for 20 hours, 
followed by incubation with evofosfamide for 4 hours 
under hypoxia and reoxygenation.
Statistical analysis
For in vivo treatment response to evofosfamide 
with fractionated and single high dose irradiation, the 
mean slopes of tumor growth curves for individual 
animals (day 0-15) were calculated and analyzed by one 
way ANOVA with Tukey post test using the GraphPad 
software. To calculate statistical significance between two 
or more groups of variables in in vitro experiments, either 
unpaired t-test or ANOVA with Tukey post test was used, 
respectively. P values <0.05 were considered significant. 
For all experiments, *P<0.05, **P<0.01, ***P<0.001.
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